The DNA methylation landscape of small cell lung cancer suggests a differentiation defect of neuroendocrine cells

Oncogene

Volumn 32, Issue 30, 2013, Pages 3559-3568

  Kalari, S ^a   Jung, M ^a   Kernstine, K H ^a,c   Takahashi, T ^b   Pfeifer, G P ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Differentiation; DNA methylation; Epigenetics; Small cell lung cancer

Indexed keywords

BIOLOGICAL MARKER; DNA; NEUROGENIC DIFFERENTIATION FACTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR HAND1; TRANSCRIPTION FACTOR REST; TRANSCRIPTION FACTOR ZNF423; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL FATE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA MICROARRAY; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG SMALL CELL CANCER; NERVE CELL DIFFERENTIATION; NEUROSECRETORY CELL; PRIMARY TUMOR; PRIORITY JOURNAL; PROMOTER REGION;

BASE SEQUENCE; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CLUSTER ANALYSIS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; HUMANS; LUNG NEOPLASMS; MICROARRAY ANALYSIS; NEUROENDOCRINE CELLS; NEUROENDOCRINE TUMORS; PROMOTER REGIONS, GENETIC; SMALL CELL LUNG CARCINOMA; TRANSCRIPTOME;

EID: 84880921962     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2012.362     Document Type: Article

References (55)

1. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24: 4539-4544. (Pubitemid 46630948)
2. Wistuba II, Gazdar AF, Minna JD. Molecular genetics of small cell lung carcinoma. Semin Oncol 2001; 28: 3-13. (Pubitemid 32730372)
3. Sekido Y, Fong KM, Minna JD. Molecular genetics of lung cancer. Annu Rev Med 2003; 54: 73-87. (Pubitemid 37386386)
4. Modi S, Kubo A, Oie H, Coxon AB, Rehmatulla A, Kaye FJ. Protein expression of the RB-related gene family and SV40 large T antigen in mesothelioma and lung cancer. Oncogene 2000; 19: 4632-4639.
5. Johnson BE, Ihde DC, Makuch RW, Gazdar AF, Carney DN, Oie H et al. myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. J Clin Invest 1987; 79: 1629-1634. (Pubitemid 17117266)
6. Little CD, Nau MM, Carney DN, Gazdar AF, Minna JD. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 1983; 306: 194-196. (Pubitemid 14228347)
7. Takahashi T, Obata Y, Sekido Y, Hida T, Ueda R, Watanabe H et al. Expression and amplification of myc gene family in small cell lung cancer and its relation to biological characteristics. Cancer Res 1989; 49: 2683-2688. (Pubitemid 19143399)
8. Sattler M, Salgia R. Molecular and cellular biology of small cell lung cancer. Semin Oncol 2003; 30: 57-71. (Pubitemid 36254675)
9. Fischer B, Marinov M, Arcaro A. Targeting receptor tyrosine kinase signalling in small cell lung cancer (SCLC): what have we learned so far? Cancer Treat Rev 2007; 33: 391-406. (Pubitemid 46760526)
10. Sutherland KD, Proost N, Brouns I, Adriaensen D, Song JY, Berns A. Cell of origin of small cell lung cancer: inactivation of Trp53 and rb1 in distinct cell types of adult mouse lung. Cancer Cell 2011; 19: 754-764.
11. Park KS, Liang MC, Raiser DM, Zamponi R, Roach RR, Curtis SJ et al. Characterization of the cell of origin for small cell lung cancer. Cell Cycle 2011; 10: 2806-2815.
12. Sato M, Shames DS, Gazdar AF, Minna JD. A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol 2007; 2: 327-343. (Pubitemid 47181718)
13. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000; 25: 315-319. (Pubitemid 30437320)
14. Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res 2000; 60: 6116-6133.
15. Laird PW. The power and the promise of DNA methylation markers. Nat Rev Cancer 2003; 3: 253-266. (Pubitemid 37328861)
16. Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 2005; 5: 223-231. (Pubitemid 40314953)
17. Burbee DG, Forgacs E, Zochbauer-Muller S, Shivakumar L, Fong K, Gao B et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001; 93: 691-699. (Pubitemid 32492810)
18. Dammann R, Takahashi T, Pfeifer GP. The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas. Oncogene 2001; 20: 3563-3567. (Pubitemid 32619409)
19. Sunaga N, Miyajima K, Suzuki M, Sato M, White MA, Ramirez RD et al. Different roles for caveolin-1 in the development of non-small cell lung cancer versus small cell lung cancer. Cancer Res 2004; 64: 4277-4285. (Pubitemid 38802434)
20. Kalari S, Pfeifer GP. Identification of driver and passenger DNA methylation in cancer by epigenomic analysis. Adv Genet 2010; 70: 277-308.
21. Rauch TA, Pfeifer GP. DNA methylation profiling using the methylated-CpG island recovery assay (MIRA). Methods 2010; 52: 213-217.
22. Rauch TA, Zhong X, Wu X, Wang M, Kernstine KH, Wang Z et al. High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci USA 2008; 105: 252-257.
23. Wu X, Rauch TA, Zhong X, Bennett WP, Latif F, Krex D et al. CpG island hypermethylation in human astrocytomas. Cancer Res 2010; 70: 2718-2727.
24. Rauch T, Wang Z, Zhang X, Zhong X, Wu X, Lau SK et al. Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarraybased methylated CpG island recovery assay. Proc Natl Acad Sci USA 2007; 104: 5527-5532. (Pubitemid 47175714)
25. Tommasi S, Karm DL, Wu X, Yen Y, Pfeifer GP. Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer. Breast Cancer Res 2009; 11: R14.
26. Rauch TA, Pfeifer GP. The MIRA method for DNA methylation analysis. Methods Mol Biol 2009; 507: 65-75.
27. Rauch TA, Wu X, Zhong X, Riggs AD, Pfeifer GP. A human B cell methylome at 100-base pair resolution. Proc Natl Acad Sci USA 2009; 106: 671-678.
28. Toedling J, Skylar O, Krueger T, Fischer JJ, Sperling S, Huber W. Ringo-an R/Bioconductor package for analyzing ChIP-chip readouts. BMC Bioinformatics 2007; 8: 221.
29. Hahn MA, Hahn T, Lee DH, Esworthy RS, Kim BW, Riggs AD et al. Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res 2008; 68: 10280-10289.
30. Reinert T, Modin C, Castano FM, Lamy P, Wojdacz TK, Hansen LL et al. Comprehensive genome methylation analysis in bladder cancer: identification and validation of novel methylated genes and application of these as urinary tumor markers. Clin Cancer Res 2011; 17: 5582-5592.
31. Rodriguez J, Munoz M, Vives L, Frangou CG, Groudine M, Peinado MA. Bivalent domains enforce transcriptional memory of DNA methylated genes in cancer cells. Proc Natl Acad Sci USA 2008; 105: 19809-19814.
32. Takeshima H, Yamashita S, Shimazu T, Niwa T, Ushijima T. The presence of RNA polymerase II, active or stalled, predicts epigenetic fate of promoter CpG islands. Genome Res 2009; 19: 1974-1982.
33. Kondo Y, Shen L, Cheng AS, Ahmed S, Boumber Y, Charo C et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet 2008; 40: 741-750. (Pubitemid 351748874)
34. Maunakea AK, Nagarajan RP, Bilenky M, Ballinger TJ, D'Souza C, Fouse SD et al. Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature 2010; 466: 253-257.
35. Heinz S, Benner C, Spann N, Bertolino E, Lin YC, Laslo P et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell 2010; 38: 576-589.
36. Lee NH, Haas BJ, Letwin NE, Frank BC, Luu TV, Sun Q et al. Cross-talk of expression quantitative trait loci within 2 interacting blood pressure quantitative trait loci. Hypertension 2007; 50: 1126-1133. (Pubitemid 350172936)
37. Piper M, Barry G, Hawkins J, Mason S, Lindwall C, Little E et al. NFIA controls telencephalic progenitor cell differentiation through repression of the Notch effector Hes1. J Neurosci 2010; 30: 9127-9139.
38. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet 2008; 9: 465-476. (Pubitemid 351693975)
39. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
40. Smith LT, Lin M, Brena RM, Lang JC, Schuller DE, Otterson GA et al. Epigenetic regulation of the tumor suppressor gene TCF21 on 6q23-q24 in lung and head and neck cancer. Proc Natl Acad Sci USA 2006; 103: 982-987. (Pubitemid 43212208)
41. Warming S, Rachel RA, Jenkins NA, Copeland NG. Zfp423 is required for normal cerebellar development. Mol Cell Biol 2006; 26: 6913-6922. (Pubitemid 44387640)
42. Huang S, Laoukili J, Epping MT, Koster J, Holzel M, Westerman BA et al. ZNF423 is critically required for retinoic acid-induced differentiation and is a marker of neuroblastoma outcome. Cancer Cell 2009; 15: 328-340.
43. Holzel M, Huang S, Koster J, Ora I, Lakeman A, Caron H et al. NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell 2010; 142: 218-229.
44. Qureshi IA, Gokhan S, Mehler MF. REST and CoREST are transcriptional and epigenetic regulators of seminal neural fate decisions. Cell Cycle 2010; 9: 4477-4486.
45. Majumder S. REST in good times and bad: roles in tumor suppressor and oncogenic activities. Cell Cycle 2006; 5: 1929-1935. (Pubitemid 44435297)
46. Coulson JM. Transcriptional regulation: cancer, neurons and the REST. Curr Biol 2005; 15: R665-R668. (Pubitemid 41219582)
47. Coulson JM, Edgson JL, Woll PJ, Quinn JP. A splice variant of the neuron-restrictive silencer factor repressor is expressed in small cell lung cancer: a potential role in derepression of neuroendocrine genes and a useful clinical marker. Cancer Res 2000; 60: 1840-1844. (Pubitemid 30207641)
48. Kreisler A, Strissel PL, Strick R, Neumann SB, Schumacher U, Becker CM. Regulation of the NRSF/REST gene by methylation and CREB affects the cellular phenotype of small-cell lung cancer. Oncogene 2010; 29: 5828-5838.
49. Neptune ER, Podowski M, Calvi C, Cho JH, Garcia JG, Tuder R et al. Targeted disruption of NeuroD, a proneural basic helix-loop-helix factor, impairs distal lung formation and neuroendocrine morphology in the neonatal lung. J Biol Chem 2008; 283: 21160-21169.
50. Stadler MB, Murr R, Burger L, Ivanek R, Lienert F, Scholer A et al. DNA-binding factors shape the mouse methylome at distal regulatory regions. Nature 2011; 480: 490-495.
51. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997; 25: 2532-2534. (Pubitemid 27303718)
52. Quinlan AR, Hall IM. BED Tools: a flexible suite of utilities for comparing genomic features. Bioinformatics 2010; 26: 841-842.
53. Linhart C, Halperin Y, Shamir R. Transcription factor and microRNA motif discovery: the Amadeus platform and a compendium of metazoan target sets. Genome Res 2008; 18: 1180-1189. (Pubitemid 351931169)
54. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
55. Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 2009; 37: 1-13.